x
Filter:
Filters applied
- Genomics and Proteomics
- cancerRemove cancer filter
- 2018 - 2023Remove 2018 - 2023 filter
Author
- Cao, Biyin1
- Chakroborty, Deepankar1
- Denu, John M1
- Elenius, Klaus1
- Elo, Laura L1
- Graves, Lee M1
- He, Yuanming1
- Jiang, Shuoyi1
- Johnson, Mark S1
- Jänne, Pasi A1
- Klein, Mark A1
- Koivu, Marika1
- Koivunen, Jussi P1
- Kurppa, Kari J1
- Mao, Xinliang1
- McDonald, Ian M1
- Moran, Michael F1
- Ojala, Veera K1
- Paatero, Ilkka1
- Tamirat, Mahlet Z1
- Tong, Jiefei1
- Wang, Siyu1
- Xu, Yujia1
- Yang, Ye1
- Zeng, Yuanying1
Keyword
- aging1
- anticancer drug1
- cancer biology1
- cell metabolism1
- cell proliferation1
- chromatin1
- clonal selection1
- CRISPR/Cas1
- deubiquitylation (deubiquitination)1
- directed evolution1
- driver mutations1
- drug target1
- epidermal growth factor receptor (EGFR)1
- ERBB1
- gene expression1
- histone deacetylase (HDAC)1
- inhibitor1
- longevity1
- maternal embryonic leucine zipper kinase (MELK)1
- metabolic disorder1
- multiple myeloma1
- OTS1671
- RNA interference (RNAi)1
- SIRT61
Genomics and Proteomics
4 Results
- JBC ReviewsOpen Access
Biological and catalytic functions of sirtuin 6 as targets for small-molecule modulators
Journal of Biological ChemistryVol. 295Issue 32p11021–11041Published online: June 9, 2020- Mark A. Klein
- John M. Denu
Cited in Scopus: 33Sirtuin 6 (SIRT6) is a nuclear NAD+-dependent deacetylase of histone H3 that regulates genome stability and gene expression. However, nonhistone substrates and additional catalytic activities of SIRT6, including long-chain deacylation and mono-ADP-ribosylation of other proteins, have also been reported, but many of these noncanonical roles remain enigmatic. Genetic studies have revealed critical homeostatic cellular functions of SIRT6, underscoring the need to better understand which catalytic functions and molecular pathways are driving SIRT6-associated phenotypes. - JBC ReviewsOpen Access
Enigmatic MELK: The controversy surrounding its complex role in cancer
Journal of Biological ChemistryVol. 295Issue 24p8195–8203Published online: April 29, 2020- Ian M. McDonald
- Lee M. Graves
Cited in Scopus: 14The Ser/Thr protein kinase MELK (maternal embryonic leucine zipper kinase) has been considered an attractive therapeutic target for managing cancer since 2005. Studies using expression analysis have indicated that MELK expression is higher in numerous cancer cells and tissues than in their normal, nonneoplastic counterparts. Further, RNAi-mediated MELK depletion impairs proliferation of multiple cancers, including triple-negative breast cancer (TNBC), and these growth defects can be rescued with exogenous WT MELK, but not kinase-dead MELK complementation. - Genomics and ProteomicsOpen Access
The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival
Journal of Biological ChemistryVol. 295Issue 7p2084–2096Published online: December 10, 2019- Yuanming He
- Siyu Wang
- Jiefei Tong
- Shuoyi Jiang
- Ye Yang
- Zubin Zhang
- and others
Cited in Scopus: 29The Maf proteins, including c-Maf, MafA, and MafB, are critical transcription factors in myelomagenesis. Previous studies demonstrated that Maf proteins are processed by the ubiquitin–proteasome pathway, but the mechanisms remain elusive. This study applied MS to identify MafB ubiquitination-associated proteins and found that the ubiquitin-specific protease USP7 was present in the MafB interactome. Moreover, USP7 also interacted with c-Maf and MafA and blocked their polyubiquitination and degradation. - Editors' PicksOpen Access
An unbiased in vitro screen for activating epidermal growth factor receptor mutations
Journal of Biological ChemistryVol. 294Issue 24p9377–9389Published online: April 5, 2019- Deepankar Chakroborty
- Kari J. Kurppa
- Ilkka Paatero
- Veera K. Ojala
- Marika Koivu
- Mahlet Z. Tamirat
- and others
Cited in Scopus: 9Cancer tissues harbor thousands of mutations, and a given oncogene may be mutated at hundreds of sites, yet only a few of these mutations have been functionally tested. Here, we describe an unbiased platform for the functional characterization of thousands of variants of a single receptor tyrosine kinase (RTK) gene in a single assay. Our in vitro screen for activating mutations (iSCREAM) platform enabled rapid analysis of mutations conferring gain-of-function RTK activity promoting clonal growth.